Literature DB >> 2384454

Clinical profile, therapeutic approach and outcome of gouty arthritis in northern India.

A Kumar1, Y N Singh, A N Malaviya, K Chaudhary, S Tripathy.   

Abstract

Thirty patients with gouty arthritis were studied over 3 years. The diagnosis was established with the help of polarised light microscopy. All the patients were males, with a median age of 45 years. They belonged to the middle or upper socio-economic class and were obese (mean body mass index 29.7). Chronic alcoholism, diabetes mellitus and hypertension were present in one patient each. No patient had symptomatic coronary artery disease. Although 6 patients had a history of renal colic, only one had gouty nephropathy with chronic renal failure. Six patients had a positive family history of gout. The disease involved mostly the joints of the lower extremity and podagra was observed in 70% of patients. Eight patients had tophi at various sites. There were 17 'over producers' and 13 'under excretors' of uric acid. The treatment consisted of patient education, symptomatic control with non steroidal anti-inflammatory drugs and/or colchicine and antihyperuricaemic therapy. The overproducers were treated with allopurinol while the under excretors were treated with [corrected] sulfinpyrazone. In general, there was a good response to therapy as indicated by lowering of serum uric acid and the number of painful episodes per year. The overall profile of the disease appears similar to that seen in the West.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2384454

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  2 in total

1.  Calcium oxalate stone and gout.

Authors:  Y M Fazil Marickar
Journal:  Urol Res       Date:  2009-09-25

2.  Utility of CT imaging in differentiating sacroiliitis associated with spondyloarthritis from gouty sacroiliitis: a retrospective study.

Authors:  Jyoti Panwar; Pulukool Sandhya; Madhavi Kandagaddala; Aswin Nair; Visalakshi Jeyaseelan; Debashish Danda
Journal:  Clin Rheumatol       Date:  2017-11-08       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.